Taysha Gene Therapies, Inc. (TSHA)

Nasdaq Biotechnology Diagnostics SIC: 2836
D
Pipeline Grade

Financial Position (from SEC Filings)

$188.8M
Cash & Equivalents
$40.9M
Quarterly Burn Rate
14 mo
Est. Cash Runway
$1,652M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT06152237 Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study) PHASE2 Active Not Recruiting 6

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for TSHA.

SEC EDGAR Filings

All SEC filings for Taysha Gene Therapies, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.